Application No.: 10/518,733 Docket No.: 36749-212211

REMARKS

Applicant elects with traverse Group I (claims 30-34), for prosecution. Applicant further

elects as species N-amidino-3,5-diamino-6-chloropyrzine-2-carboximide hydrochloride

dehydrate and elects adenosine receptor agonist. Claims 30-34 are readable on these species.

Applicant traverses the restriction between Group I and Group III. These groups have

unity of invention as they are a product and a process of use of the product, and they share a

common technical feature. Likewise, Group V shares unity with Groups I and III as a product of

the claimed process for using the claimed composition. Applicant reserves the right to rejoin

non-elected claims and/or to file divisional applications.

It is believed that this response is a complete reply to the restriction requirement and thus

Applicant respectfully requests that prosecution proceed. Applicant further submits that the

claims are in condition for allowance and requests that the Examiner so indicate and issue a

notice of allowability and that the application be passed to issue. Should the Examiner have any

questions which might be amenable to a telephone interview, the Examiner is invited to contact

undersigned counsel to discuss such issues.

Dated: 4/30/2007

Customer No. 26694

DC2/854532v1

Respectfully submit

Michael A. Gollin

Registration No.: 31,957

Attorney for Applicant

VENABLE LLP 575 7th Street NW

Washington, DC 20004-1601

(202) 344-4000

(202) 344-8300 (Fax)